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Abstract 24 
2-ethylhexyl-2,3,4,5-tetrabromobenzoate (EH-TBB) and a mixture of EH-TBB, Bis(2-25 
ethylhexyl)tetrabromphthalate (BEH-TEBP) and Triphenyl phosphate (TPhP), prepared in 26 
a ratio similar to the Firemaster-550™ (FM550) flame retardant formulation, were exposed 27 
to human skin subcellular fractions (S9) to evaluate their dermal in vitro metabolism for 28 
the first time. After 60 mins of incubation, tetrabromobenzoic acid (TBBA) and diphenyl 29 
phosphate (DPhP) were identified as the major metabolites of EH-TBB and TPhP, 30 
respectively using UPLC-Q-Exactive Orbitrap™-MS analysis. Dermal biotransformation of 31 
EH-TBB and TPhP was catalyzed by skin carboxylesterases rather than CYP450 enzymes, 32 
while no stable metabolites could be identified for BEH-TEBP. Metabolite formation rates 33 
of EH-TBB as individual compound and as a component of FM550 fitted the Michaelis-34 
Menten model, while no steady state could be reached for TPhP under experimental 35 
conditions. Estimated maximum metabolic rate (Vmax) for TBBA formation upon exposure 36 
to FM550 was lower than Vmax for EH-TBB (1.08 and 15.2 pmol min-1 mg protein-1, 37 
respectively). This indicates dermal metabolism would contribute less to the clearance of 38 
EH-TBB body burden than hepatic metabolism (Vmax = 644 pmol min-1 mg protein-1). 39 
Implications for human exposure include EH-TBB accumulation in skin tissue and human 40 
exposure to dermal metabolic products, which may have different toxicokinetic and 41 
toxicodynamic parameters than parent flame retardants.  42 
 43 
Keywords: Flame retardants; Firemaster 550; EH-TBB; dermal metabolism; human exposure. 44 
 45 
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Introduction 46 
2-ethylhexyl-2,3,4,5-tetrabromobenzoate (EH-TBB) is an additive flame retardant 47 
produced by Chemtura™ Corporation. It is available in 2 commercial mixtures: Firemaster 48 
550™ (FM550) and Firemaster BZ-54™ (FMBZ-54). In FM550, EH-TBB is mixed with bis(2-49 
ethylhexyl) tetrabromophthalate (BEH-TEBP), triphenyl phosphate (TPhP) and assorted 50 
isopropyl triphenylphosphate (ITP) isomers in the ratio: 36% EH-TBB, 14% BEH-TEBP, 51 
18% TPhP and 32% ITPs by weight (Belcher et al., 2014). As additive FRs, EH-TBB and the 52 
other components of FM550 may leach out from treated consumer goods and contaminate 53 
the environment. They have been detected globally in various environmental matrices 54 
including indoor dust,(Carignan et al., 2013; Tao et al., 2016; Hammel et al., 2017) indoor 55 
air,(Cequier et al., 2014; Tao et al., 2016) outdoor air,(Ma et al., 2012) chicken eggs,(Zheng 56 
et al., 2016) aquatic biota (Strid et al., 2013) and foodstuffs (Xu et al., 2015). 57 
Similar to other emerging FRs, the environmental occurrence of EH-TBB and FM550 58 
components is expected to be mainly in indoor dust. Residential dust in the UK contained 59 
median concentrations of EH-TBB and BEH-TEBP at 4 - 23 (median = 5.8) and 80 – 3187 60 
(median = 320) ng/g, respectively (Al-Omran and Harrad, 2016). In the U.S.A., house dust 61 
samples from California collected in 2011 showed higher levels of FM550 components than 62 
those collected in 2006. Specifically, concentration ranges of EH-TBB and BEH-TEBP in 63 
2011 were 45-5900 (median = 100) and <2-3800 (median = 260) ng/g, while those in 2006 64 
were 4-740 (median = 48) and 36-1900 (median = 140), respectively (Dodson et al., 2012). 65 
Extremely high concentrations of EH-TBB and BEH-TEBP were reported in dust from an 66 
American gymnasium ranging from 20,800 to 85,600 (median = 28,900) ng/g for EH-TBB 67 
and 17,300 to 44,900 (median = 30,000) ng/g for BEH-TEBP (Carignan et al., 2013). This is 68 
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of concern due to the potential toxicity of FM550 components to humans and wildlife. Both 69 
EH-TBB and BEH-TEBP expressed in vitro antiestrogenic and antiandrogenic effects in the 70 
yeast estrogen screen and yeast androgen screen assays (reflected in inhibition of β-71 
galactosidase production by the assays), as well as increased oestrogen production in the 72 
human H295R steroidogenesis assays (Saunders et al., 2013). By use of primary porcine 73 
testicular cells, Mankidy et al. also investigated the effects of EH-TBB and BEH-TEBP on 74 
steroidogenesis via different mechanisms; EH-TBB induced the production of cortisol and 75 
aldosterone while BEH-TEBP promoted sex hormones synthesis (Mankidy et al., 2014). 76 
FM550-administered rats showed many negative health effects e.g. advanced female 77 
puberty, weight gain, altered exploratory behaviours and hepatic carboxylesterases activity 78 
(Patisaul et al., 2013). FM550 (mainly driven by the TPhP component) was found to bind to 79 
human peroxisome proliferator-activated receptor γ (PPARγ1) and subsequently induced 80 
PPARγ1 transcription activity. The same study also reported adipogenesis induction in 81 
primary mouse bone marrow cultures by FM550 and TPhP (Pillai et al., 2014). 82 
Accidental indoor dust ingestion is reported as a major exposure pathway of humans to 83 
EH-TBB, BEH-TBP and TPhP (Besis et al., 2017; Tao et al., 2017). However, the significance 84 
of dermal absorption as a pathway of human exposure to halogenated flame retardants via 85 
contact with contaminated dust or flame retarded consumer products has been recently 86 
highlighted (Abdallah et al., 2016; Frederiksen et al., 2016; Abdallah and Harrad, 2018; 87 
Frederiksen et al., 2018). This is of particular relevance to EH-TBB and FM550, which are 88 
widely used to flame proof upholstered furniture including childcare products (e.g. car 89 
seats and nap mats) (Hammel et al., 2017; Stubbings et al., 2018). A recent study by our 90 
research group revealed dermal uptake of some brominated FRs via contact with 91 
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upholstered furniture may even exceed exposure via dust ingestion or dietary exposure 92 
(Abdallah and Harrad, 2018). Frederiksen et al. reported on the dermal uptake of EH-TBB, 93 
BEH-TEBP and TPhP using a human skin ex vivo model. Based on the mass balance exercise, 94 
dermal biotransformation was suggested for all 3 flame retardants based on their ester 95 
chemical structure (Frederiksen et al., 2016; Frederiksen et al., 2018). This is supported by 96 
Hopf et al. who found that diethyl hexyl phthalate is completely hydrolysed to monoethyl 97 
hexyl phthalate by freshly excised human skin, such that only the metabolites penetrate 98 
through the skin to reach systemic circulation (Hopf et al., 2014). While it is reasonable to 99 
hypothesize that dermal exposure to EH-TBB and FM550 components via contact with 100 
furniture may be substantial, very little is known about human dermal metabolism of these 101 
flame retardants. While the hepatic metabolism of these FRs has been studied using various 102 
in vitro techniques,(Roberts et al., 2012; Van den Eede et al., 2013) the products and role of 103 
extrahepatic dermal metabolism of FRs remains largely unknown. Consequently, 104 
understanding of the skin biotransformation pathways, rates and products of the esterified 105 
flame retardants EH-TBB, BEH-TEBP and TPhP is important for comprehensive risk 106 
assessment of these chemicals. Against this backdrop, the current study aims to provide the 107 
first insights into the dermal biotransformation of EH-TBB, BEH-TEBP and TPhP using in 108 
vitro human skin S9 fractions. Specific objectives include: (a) dermal metabolite 109 
identification; (b) metabolic rate estimation for EH-TBB as a single compound (FMBZ-54) 110 
and in a mixture with BEH-TEBP and TPhP (FM550); and (c) an evaluation of the 111 
implications of dermal metabolism for human dermal exposure to the studied flame 112 
retardants.    113 
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Materials and Methods 114 
Chemicals and Standards 115 
All solvents and reagents used in this study were purchased from Fisher Scientific 116 
(Loughborough, UK) and were of HPLC grade or higher. 2-Ethylhexyl-2,3,4,5-117 
tetrabromobenzoate (EH-TBB) and  bis(2-ethylhexyl) tetrabromophthalate (BEH-TEBP) 118 
for dosing solutions (purity >95%) were obtained as neat standards from AccuStandard, 119 
Inc. (New Haven, CT, USA). High-resolution Orbitrap-MS scan of the neat standards 120 
revealed no brominated impurities/degradation products. Moreover, no effects on the 121 
metabolic activity of the human skin enzymes were observed upon exposure to the EH-TBB 122 
and BEH-TEBP standard solutions. High purity standards of EH-TBB, BEH-TEBP, triphenyl 123 
phosphate (TPhP), 2-ethylhexyl-2,3,4,5-tetrabromo[13C6]benzoate (13C-EH-TBB), bis(2-124 
ethylhexyl-d17)-tetrabromo[13C6]phthalate (13C-BEH-TEBP), tetrabromobenzoic acid 125 
(TBBA), 13C-labelled tetrabromobenzoic acid (13C-TBBA ) and α-1,2,5,6,9,10-126 
hexabromo[13C12]cyclododecane] (13C-α-HBCDD) were purchased from Wellington 127 
Laboratories (Guelph, ON, Canada). Triphenyl phosphate-d15 (TPhP-d15) and diphenyl 128 
phosphate (DPhP) were purchased from Sigma Aldrich (Dorset, UK). RapidStart™ NADPH 129 
regenerating system was purchased from XenoTech (Kansas, KS, USA), William’s E medium 130 
was obtained from Thermo Fisher Scientific (Paisley, UK). Human skin S9 fractions (HS-S9) 131 
was purchased from Biopredic International (Saint Grégoire, France), comprising a pooled 132 
sample prepared from the abdominal skin of 3 white female donors after plastic surgery 133 
(age range 33-46 years – further details are provided in the supporting information). 134 
Individual EH-TBB dosing solutions were prepared by dissolving EH-TBB in dimethyl 135 
sulfoxide (DMSO). Firemaster 550™ (FM550)-equivalent mixtures were prepared by 136 
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dissolving EH-TBB, BEH-TEBP and TPhP in the ratio 53:20.5:26.5 by weight in DMSO, 137 
similar to the reported ratio for the technical FM550 mixture (Belcher et al., 2014). 138 
Isopropyl triphenylphosphate isomers (ITP) of sufficient high purity were not available to 139 
our lab at the time of conducting this study; hence these were not included in the FM550 140 
dosing solutions applied in the current study. FM550 solutions were prepared such that 141 
each dosing level contained concentrations of EH-TBB similar to those in the individual EH-142 
TBB dosing solutions. 143 
In vitro Incubation Experiments 144 
Pre-incubations were performed at different HS-S9 concentrations and different times. 145 
After optimization of the reaction parameters, the following exposure protocol was 146 
applied: 0.11 mg of HS-S9, William’s E medium and 10 µL of EH-TBB/FM550 dosing 147 
solutions (final concentration 10 µM of EH-TBB) were pre-incubated for 5 minutes at 37 ˚C. 148 
NADPH regenerating system (final concentration: 2.0 mM nicotinamide adenine 149 
dinucleotide phosphate, 10.0 mM glucose-6-phosphate and 2 units/mL glucose-6-150 
phosphate dehydrogenase) was added to make a final volume of 1 mL. The samples were 151 
then incubated at 37 ˚C, 5% CO2 and 98% relative humidity for 60 min. At the end of the 152 
incubation, 1 mL of ice-cold ethyl acetate was added to stop the reaction prior to sample 153 
extraction.  154 
Sample extraction 155 
Incubated EH-TBB samples were spiked with 20 ng each of 13C-EH-TBB and 13C-TBBA 156 
while FM550 samples were spiked with 20 ng each of 13C-EH-TBB, 13C-TBBA, 13C-BEH-157 
TEBP and TPhP-D15 as internal (surrogate) standards. Spiked samples were mixed with 3 158 
mL of ethyl acetate by vortexing for 60 s, followed by ultrasonication for 5 min and 159 
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centrifuged at 4000 g for 5 min. The organic layer was collected and the extraction 160 
procedure was repeated twice. The combined extracts were evaporated to dryness under a 161 
gentle stream of nitrogen then reconstituted in 100 µL of methanol containing 20 ng of 13C-162 
α-HBCDD as a recovery determination (syringe) standard for QA/QC purposes. 163 
Instrumental analysis 164 
Samples were analyzed on a UPLC-Orbitrap-HRMS platform (Thermo Fisher Scientific, 165 
Bremen, Germany) composed of a Dionex Ultimate 3000 liquid chromatograph composed 166 
of a HPG-3400RS dual pump, a TCC-3000 column oven and a WPS-3000 auto sampler, 167 
coupled to a Q-Exactive Plus Orbitrap mass spectrometer. Chromatographic separation was 168 
performed on an Accucore RP-MS column (100 x 2.1 mm, 2.6 µm) with water (mobile 169 
phase A) and methanol (mobile phase B). A gradient programme at 400 µL/min flow rate 170 
was applied as follows: start at 20% B; increase to 100% B over 9 min, held for 3 min; then 171 
decrease to 20% B over 0.1 min; maintained constant for a total run time of 15 min. The 172 
mobile phase composition and gradient were selected based on the polarity and solubility 173 
of the target compounds and their reported metabolites. Methanol is used as the organic 174 
phase because none of the target compounds or their reported metabolites (e.g. 175 
monohydroxy or dihydroxy metabolites) are freely water soluble (Roberts et al., 2012; Van 176 
den Eede et al., 2013). Orbitrap-MS data from both electrospray ionization (ESI) and 177 
atmospheric pressure chemical ionization (APCI) modes was acquired for each sample. 178 
Negative APCI was used for determination of EH-TBB, 13C-EH-TBB, BEH-TEBP, 13C-BEH-179 
TEBP and screening for potential metabolites. The more universal, softer ESI mode was 180 
used in positive/negative alternative switching mode for screening and identification of the 181 
produced metabolites, as well as determination of TPhP and TPhP-d15. The optimized 182 
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Orbitrap-MS parameters for the analysis of EH-TBB, FM550 and their potential metabolites 183 
are provided in Table SI-1. 184 
Compound Discoverer 2.0 software (Thermo Fisher Scientific, Bremen, Germany) was used 185 
to detect potential metabolites and elucidate their chemical formulae, while quantification 186 
of target FRs was performed using Quan Browser 3.0 (Thermo Fisher Scientific, Bremen, 187 
Germany). 188 
QA/QC 189 
Metabolic activity of phases I enzymes including NADPH-cytochrome C reductase, carboxyl 190 
esterase and FMO3 were measured using guidelines and specific kits provided by Biopredic 191 
International and showed normal activities of all enzymes after HS-S9 thawing. 192 
Quality assurance samples comprising William’s E medium spiked with EH-TBB and 193 
FM550 mixture at all dosing levels were analyzed, with recoveries of dosing chemicals 194 
falling between 80 to 115% of the theoretical dosing concentrations. Internal standard 195 
recoveries in all HS-S9 incubation experiments ranged from 65-115%. 196 
In all incubation experiments, a solvent blank comprising William’s E medium was 197 
performed and analysed alongside the sample batch. No parent compounds or metabolites 198 
were found in solvent blanks with the exception of TPhP at negligible levels (< 1% of the 199 
lowest dosing level). Therefore, no blank correction was needed. Additionally, no 200 
metabolites were found in the non-enzymatic (all experimental components except HS-S9) 201 
and heat-inactivated (HS-S9 inactivated by heating at 70 °C for 30 min) controls run in 202 
parallel to each sample batch.  203 
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Biotransformation kinetic modelling 204 
The metabolite formation rate and substrate concentration of the studied chemicals were 205 
fitted to different biotransformation kinetic models (Northrop, 1983; Lipscomb and Poet, 206 
2008) by nonlinear regression analysis using the SigmaPlot Enzyme Kinetics Module v.1.1 207 
(Systat Software Inc., Richmond, CA) to determine the enzyme kinetic model that best 208 
describe the formation rates of the metabolites. The models used were the Michaelis-209 
Menten equation (Equation 1), the Hill equation (Equation 2), and the substrate-inhibition 210 
kinetic equation (Equation 3) : 211 
v =
Vmax×[S]
Km+[S]
           (Equation 1) 212 
v =
Vmax×[S]
n
K′+[S]n
           (Equation 2) 213 
v =
Vmax
1+
Km
[S]
+
[S]
Ki
           (Equation 3) 214 
where v is initial velocity of the reaction, Vmax is the maximum metabolic rate, [S] is the 215 
substrate concentration, Km is the Michaelis-Menten constant, K’ is the Hill dissociation 216 
constant, n is the Hill coefficient and Ki is the inhibitory dissociation constant. Selection of 217 
the best fitted model was determined by statistical criteria to evaluate the goodness of the 218 
fit. The two statistical criteria used were Akaike Information Criterion corrected for small 219 
sample size (AICc) and the standard deviation of the residuals (Sy.x). The model with the 220 
lowest values for AICc and for the standard deviation of the residuals was considered to be 221 
the model that best fit the data. When the formation rate of a primary metabolite is best 222 
described by the Michaelis-Menten model (Equation 1), the part of the in vitro intrinsic 223 
clearance (Clint,M) due to the formation of that metabolite can be calculated as follows: 224 
CLint,M =
v
[S]
=
Vmax
Km+[S]
  (Equation 4) 225 
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 If the levels of the substrate of interest in human blood are negligible compared to the 226 
apparent Km value associated with the formation of the metabolite, then (Km + [S]) ≈ Km 227 
therefore Equation 4 can be written as follows (Lipscomb and Poet, 2008):  228 
CLint =
v
[S]
=
Vmax
Km
 (Equation 5) 229 
The total Clint value of the substrate of interest can then be calculated as the sum of the 230 
Clint of each of its primary metabolites. 231 
The intrinsic in vitro clearance of a xenobiotic by an organ on kilogram human body weight 232 
(CLint-organ) basis can be scale up by the following equation: 233 
CLint−organ = CLint × p × w (Equation 6) 234 
Where p is the amount of protein per gram of an organ and w is the average weight of that 235 
organ per kilogram body weight. 236 
The blood flow of an organ per kilogram body weight (kg b.w) Qh was taken into account 237 
for extrapolation of in vitro clearance to in vivo clearance (CLh) as follows (Lipscomb and 238 
Poet, 2008): 239 
CLorgan =
Qh×CLint−organ
CLint−organ+Qh
 (Equation 7) 240 
 241 
Results and Discussion 242 
Dermal metabolic profiles of EH-TBB and FM550 243 
Due to the chemical structure of EH-TBB, BEH-TEBP and TPhP (Figure SI-1), we 244 
hypothesized that their metabolism by HS-S9 would be catalysed by carboxyesterases 245 
and/or cyctochrome P450 enzymes. Full scan mode with either APCI or alternate switching 246 
positive/negative ESI ionization were used to screen for EH-TBB and FM550 dermal 247 
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metabolites. No potential metabolites were found in (+)ESI or (-)APCI mode. For EH-TBB 248 
samples, in (-)ESI mode there was one potential metabolite with the ion mass of 436.66814 249 
and the proposed ion formula [C7HBr4O2]ˉ. By comparing with the authentic standard, this 250 
was confirmed as the [M-H]ˉ molecular ion for TBBA (Figure 1). This is in agreement with 251 
the results of Roberts et al., who reported TBBA as the only in vitro metabolite of EH-TBB 252 
by human and rat liver microsomes (Roberts et al., 2012). 253 
Following exposure of HS-S9 to FM550 mixture components, TBBA was also identified as 254 
the sole metabolite of EH-TBB. In addition, another potential metabolite with the ion mass 255 
of 249.03204 was detected in (-)ESI mode. The proposed chemical structure for this ion 256 
was [C12H10O4P]-. In order to elucidate the chemical structure of this compound, a MS/MS 257 
experiment was carried out in (-)ESI-SIM-MS2 mode. A combination of low, medium and 258 
high collision energies were applied stepwise to achieve a diverse range of fragmentation 259 
ions. Specific Orbitrap-MS parameters for this experiment are provided in Table SI-2. The 260 
ion m/z = 249.03204 was fragmented mainly into three ions: 154.98895, 93.03284 and 261 
78.95728. The proposed chemical formula for these fragments were: [C6H4O4P]-, [C6H5O]- 262 
and [PO3]-, respectively (Figure 2). Based on the proposed parent ion formula and the MS2 263 
fragmentation data, this metabolite was identified as diphenyl phosphate (DPhP), assigned 264 
as a primary metabolite of TPhP. Metabolite identity was further confirmed via comparison 265 
and augmentation with an authentic chemical standard of DPhP. Previous studies have 266 
reported that in vitro metabolism of TPhP by human liver microsomes or chicken embryo 267 
hepatocytes formed DPhP, hydroxylated TPhP (OH-TPhP) and dihydroxylated TPhP 268 
((OH)2-TPhP) (Van den Eede et al., 2013; Su et al., 2014). In vivo metabolism of TPhP in fish 269 
produced DPhP, OH-TPhP, (OH)2-TPhP and monophenyl phosphate among which DPhP 270 
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was the major metabolite (Wang et al., 2016). However, DPhP was detected as the sole 271 
metabolite of TPhP by HS-S9 in the present study.  272 
By comparison of the in vitro human dermal (this study) and hepatic metabolic profiles of 273 
EH-TBB and TPhP,(Roberts et al., 2012; Van den Eede et al., 2013) it was obvious that the 274 
oxidative metabolites could not be identified in the HS-S9 experiments under the current 275 
experimental conditions. Proteomic profiling of the metabolic activity of dermal HS-S9 276 
fractions show that both CYP450 and carboxylesterases are active, albeit at much lower 277 
levels than in the liver cells (Oesch et al., 2018). Moreover, the reported levels of CYP450 278 
enzymes in human skin were at least 300 fold lower than that in human liver. In contrast, 279 
the relative level of carboxylesterase 1 (CES1) in human skin and liver was 0.62 with no 280 
significant level difference (P = 0.21) (van Eijl et al., 2012). Such low level of CYP450 281 
enzymes and similar level of CES1 in the skin in comparison with liver might explain why 282 
no oxidative metabolites were observed in the present study. To test this hypothesis, we 283 
performed NADPH-independent (i.e. without NADPH cofactor) in vitro incubation of EH-284 
TBB and FM550 with HS-S9 under the same conditions. The absence of NADPH did not 285 
result in significant changes in the formation rates of TBBA, DPhP or depletion rates of the 286 
parent compounds (P>0.05). These results reveal differences from hepatic metabolism as 287 
dermal carboxylesterases seem to be the major metabolizing enzymes of the target FRs in 288 
human skin. This does not eliminate the possibility of oxidative metabolite formation upon 289 
dermal contact under real-life situations (i.e. upon exposure to larger doses) but if formed, 290 
they are likely to be at lower rates and concentrations than de-esterified metabolites.  291 
Finally, no stable metabolites of BEH-TEBP were identified in HS-S9 exposed to FM550 292 
mixture at any of the studied concentrations (0.3 – 4.5 µM – Table SI-2), despite the high 293 
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sensitivity and selectivity of the Orbitrap-MS platform applied in this study. This is in 294 
agreement with the results of Roberts et al. who did not detect any metabolites for BEH-295 
TEBP in human and rat hepatic subcellular fractions. Interestingly, mono(2-ethylhexyl) 296 
tetrabromophthalate, was only detected in purified hepatic porcine carboxylesterase, 297 
although at a very slow formation rate of 1.08 pmol min-1 mg protein-1 (Roberts et al., 298 
2012). This may reflect inter-species variation in the biotransformation of this flame 299 
retardant and warrants further studies to elucidate the hepatic and extrahepatic metabolic 300 
profiles of BEH-TEBP in human. 301 
Biotransformation kinetics of EH-TBB and FM 550 by HS-S9 302 
In a previous communication, our research group reported the hepatic metabolic rates of 303 
the brominated FR, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane (TBECH), were largely 304 
dependent on whether the metabolizing enzymes were challenged with a single compound 305 
or a mixture of components (Nguyen et al., 2017). Therefore, a series of incubation 306 
experiments of HS-S9 with different concentrations of EH-TBB and FM550 components 307 
(Table SI-3) were performed. With these experiments, we aimed to investigate whether the 308 
metabolic rate will be different upon challenging the HS-S9 with a multi-component 309 
mixture representing FM550 (i.e. mimicking real-life situation) compared to exposure to a 310 
single flame retardant (EH-TBB). The concentrations of TBBA and DPhP were quantified 311 
using isotope dilution series method with 13C-TBBA and d15-TPhP as internal (surrogate) 312 
standards. The results from kinetic modelling in SigmaPlot® software revealed the 313 
formation of TBBA in both pure EH-TBB and FM550 mixture experiments was best fitted 314 
by the Michaelis-Menten model (Figure 3). The model-derived kinetic parameters for the 315 
formation of TBBA are presented in Table 1. Estimated maximum metabolic rate (Vmax) for 316 
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the formation of TBBA upon exposure to FM550 mixture was significantly lower (p<0.05) 317 
than Vmax upon exposure to individual EH-TBB (1.80 and 15.2 pmol min-1 mg protein-1, 318 
respectively). However, in both cases, Vmax was substantially less than that reported 319 
previously for EH-TBB metabolism by human liver microsomes (644 pmol min-1 mg 320 
protein-1) (Roberts et al., 2012). The estimated Michaelis constant (Km) for FM550 is lower 321 
than Km for EH-TBB metabolism by HS-S9 (Table 1). Such significant decreases in both Km 322 
and Vmax suggest that the rate of metabolite formation (TBBA) from FM550 by HS-S9 has 323 
potentially been influenced by competitive substrate inhibition. The competitive inhibitors 324 
could be BEH-TEBP and/or TPhP in the FM550 dosing solutions. 325 
The formation rate of DPhP (primary metabolite of TPhP) did not fit any of the assessed 326 
enzyme kinetic models (Michaelis-Menten, Hill or substrate-inhibition). Indeed, it did not 327 
show any signs of reaching a plateau to indicate a steady state was reached. Another series 328 
of incubation experiments with higher doses of FM550 were carried out at equivalent TPhP 329 
concentrations of 16.8, 25 and 33.6 μM. Close to linearity increment of DPhP formation rate 330 
was still observed and steady state conditions could not be achieved. This observation is in 331 
agreement with a previous study on TPhP biotransformation in human serum, where the 332 
formation rate of DPhP did not reach a plateau even at concentrations up to 100 μM of 333 
TPhP (Van den Eede et al., 2016). The lack of fit to the investigated kinetic models 334 
precluded the estimation of metabolic kinetic parameters for TPhP under the applied 335 
experimental conditions. 336 
In vitro – in vivo extrapolation for dermal clearance of EH-TBB 337 
As the formation rates of TBBA were best described by the Michaelis-Menten model, the 338 
model was applied to estimate in vivo dermal clearance of EH-TBB assuming average adult 339 
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bodyweight of 70 kg. We then compared our results for dermal clearance to those reported 340 
previously by Roberts et al. for human hepatic clearance of EH-TBB (Roberts et al., 2012). 341 
The following parameters were applied: 24.84 mg protein/g skin for HS-S9 (calculated as 342 
total of microsomes and cytosol),(Jewell et al., 2007) 37 g skin/kg bodyweight, 52.5 mg 343 
protein/g liver for HLM, 25.7 g liver/kg bodyweight, Qh = 20.7 mL/min/kg bodyweight and 344 
Qskin = 4.37 mL/min/kg bodyweight (Manevski et al., 2015). Our model calculations 345 
estimated in vivo dermal clearance of individual EH-TBB and EH-TBB in FM-550 to be 0.48 346 
and 0.92 mL/min/kg bodyweight, respectively (Table 2). These rates were much smaller 347 
than the skin blood flow (4.37 mL/min/kg bodyweight), suggesting EH-TBB is not readily 348 
cleared by dermal metabolism and is likely to accumulate in the skin tissue. Indeed, the 349 
extraction ratios (defined as the ratio between the in vivo clearance of a xenobiotic to the 350 
blood flow for a specific organ)(Manevski et al., 2015) of EH-TBB by human skin were only 351 
11% and 21% for individual and mixture exposures, respectively. This is also in agreement 352 
with the results of Frederiksen et al. (2016) who reported the accumulation of EH-TBB in 353 
the skin using a human ex vivo dermal model. In contrast, human liver showed higher EH-354 
TBB extraction ratio up to 80% with in vivo hepatic clearance of 16.4 mL/min/kg 355 
bodyweight (Table 2). These results suggested that dermal metabolism contributed 356 
marginally to the clearance of internal EH-TBB body burden in comparison with liver 357 
metabolism. 358 
Study limitations 359 
It is important to note that due to limited availability, the skin HS-S9 applied in this study 360 
was pooled from the abdominal skin of 3 white female donors (age range 33-46 years). The 361 
dermal metabolic activity may vary widely depending on age, race, gender and skin 362 
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location (Oesch et al., 2018). Additionally, our in vitro – in vivo metabolic clearance 363 
calculations were based on the assumption that the unbound fraction of chemical pollutant 364 
to blood proteins equals 1, meaning all EH-TBB in the blood was free and available for 365 
metabolism. This can cause overestimation of the estimated xenobiotic clearance. 366 
Furthermore, TBBA was treated as the only primary metabolite of EH-TBB. While our 367 
experimental measurements support this assumption, it is possible that other metabolites 368 
(e.g. oxidative or debrominated metabolites) may be formed under real conditions of 369 
prolonged skin contact with high concentration of EH-TBB (e.g. sleeping on a flame 370 
retarded mattress). The potential formation of other primary metabolites under different 371 
conditions may also influence the estimated metabolic rates for EH-TBB in the current 372 
study. 373 
Implications for human exposure 374 
Even though the outer most layer of skin (stratum corneum) serves as a barrier to prevent 375 
unwanted chemicals from entering the human body, recent studies have confirmed the 376 
dermal uptake of several lipophilic pollutants such as hexabromocyclododecanes 377 
(HBCDDs), tetrabromobisphenol-A (TBBPA), organophosphate flame retardants or novel 378 
brominated flame retardants via contact with skin (Abdallah et al., 2015; Abdallah et al., 379 
2016; Frederiksen et al., 2016; Knudsen et al., 2017). Frederiksen et al. reported roughly 380 
10% dermal absorption and 0.1 - 0.2% penetration of several FRs including EH-TBB 381 
following a single dose (of several hundred nanograms) application to ex vivo human skin 382 
for 72 h (Frederiksen et al., 2016). Higher dermal uptake at 20% with 0.2% penetration of 383 
administered 14C-labelled EH-TBB to in vitro human skin after 24 h exposure was also 384 
reported (Knudsen et al., 2016). Nevertheless, it is proven that EH-TBB as well as other 385 
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organic FRs can penetrate the skin barrier and be “trapped” within the skin tissue until 386 
reaching the blood circulation (i.e. become bioavailable). In such an event, skin metabolism 387 
may play an important role in the clearance of the trapped dose within the skin tissue, yet it 388 
may also help create a concentration gradient through the different layers of the skin tissue 389 
to facilitate further uptake of the parent FR. Moreover, the slow in vitro clearance rates in 390 
the skin could translate into slow EH-TBB in vivo percutaneous metabolism and 391 
subsequently result in inefficient removal of EH-TBB from the skin. This partially explains 392 
the reported accumulation of EH-TBB in the skin tissue prior to reaching the systemic 393 
circulation (Knudsen et al., 2016). In addition, very little is known about the toxicokinetics 394 
and toxicodynamics of the dermal biotransformation products (i.e. TBBA and DPhP). This is 395 
of concern as these metabolites may lead to potential adverse health effects similar to that 396 
reported previously for PBDE metabolites (Saquib et al., 2018). Therefore, further studies 397 
on dermal uptake and metabolism of emerging flame retardants are required to fully 398 
understand both the toxicological and exposure implications of dermal biotransformation 399 
of these hazardous chemicals.  400 
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Tables 550 
Table 1: Kinetic parameters derived from Michaelis-Menten model for the formation of 551 
TBBA following incubation of HS-S9 with pure EH-TBB and FM550 mixture in the present 552 
study compared to the reported parameters for EH-TBB incubation with human liver 553 
microsomes (HLM).(Roberts et al., 2012)  554 
 555 
Substrate Model Km (µM) ± standard 
deviation 
Vmax (pmol/min/mg protein) ± 
standard deviation 
EH-TBB HS-S9 4.57 ± 1.2 15.2 ± 5 
FM550 HS-S9 0.84 ± 0.19 1.80 ± 0.05 
EH-TBB HLM 11.1 ± 3.9 644 ± 144 
 556 
 557 
 558 
Table 2: Estimated in vitro and in vivo clearance of EH-TBB by human skin (the current 559 
study) compared to those reported in human liver (Roberts et al., 2012). 560 
 561 
Chemical Organ CLint-organ (in vitro, 
mL/min/kg b.w) 
CLorgan (in vivo, 
mL/min/kg b.w) 
EH-TBB Skin 0.54 0.48 
EH-TBB in FM550 Skin 1.18 0.92 
EH-TBB  Liver 78.3 16.4 
 562 
 563 
 564 
 565 
 566 
 567 
 568 
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Figures 569 
Figure 1: TBBA detected as the sole metabolite of EH-TBB in Human Skin S9 fraction (HS-570 
S9) exposed to 10 µM of EH-TBB. 13C-TBBA is the isotope-labelled form used for identity 571 
confirmation and quantification of TBBA.  572 
 573 
 574 
 575 
 576 
 577 
 578 
 579 
 580 
 581 
 582 
 583 
13
C-TBBA 
TBBA 
26 
 
Figure 2: (-)ESI-MS/MS2 spectrum of the ion 249.03204 by UPLC-Orbitrap HRMS 584 
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Figure 3: Kinetics of TBBA formation in EH-TBB (A) and FM550 mixture (B) incubation 597 
experiments with HS-S9 using the Michaelis-Menten model. Error bars represent 1 598 
standard deviation (n=3). 599 
 600 
 601 
 602 
 603 
 604 
 605 
 606 
 607 
 608 
 609 
 610 
 611 
 612 
 613 
 614 
 615 
 616 
 617 
 618 
 619 
 620 
 621 
 622 
 623 
 624 
 625 
 626 
 627 
 628 
 629 
 630 
 631 
 632 
 633 
 634 
 635 
 636 
 637 
 638 
 639 
 640 
 641 
